Related topics: Medtronic, growth stocks, investments, StockScouter, health care
Reports from a major meeting of cardiologists in New Orleans this month suggested that Medtronic's slow-growing core business is about to get a welcome shot in the arm.
The Minneapolis company used the conference to introduce results from a study showing its next-generation stent is superior to existing versions in treating patients with coronary artery disease.
The development should help Medtronic (MDT, news) increase its share of the $3.8 billion global market for drug-eluting stents to 21% from 17% by 2014, Wells Fargo analyst Larry Biegelsen said in a note to clients. Stents are tiny tubes that prop open clogged arteries. When stents are coated with drugs, the arteries are less likely to reclog.
10 stocks to watch in the week ahead
via money.msn.com
